| Literature DB >> 25107573 |
Chise Tateno1, Toshinobu Yamamoto2, Rie Utoh3, Chihiro Yamasaki4, Yuji Ishida5, Yuka Myoken6, Ken Oofusa7, Miyoko Okada2, Naohisa Tsutsui2, Katsutoshi Yoshizato8.
Abstract
Peroxisome proliferator (PP)-activated receptor-α (PPARα) agonists exhibit species-specific effects on livers of the rodent and human (h), which has been considered to reside in the difference of PPARα gene structures. However, the contribution of h-hepatocytes (heps) to the species-specificity remains to be clarified. In this study, the effects of fenofibrate were investigated using a hepatocyte-humanized chimeric mouse (m) model whose livers were replaced with h-heps at >70%. Fenofibrate induced hepatocellular hypertrophy, cell proliferation, and peroxisome proliferation in livers of severe combined immunodeficiency (SCID) mice, but not in the h-hep of chimeric mouse livers. Fenofibrate increased the expression of the enzymes of β- and ω-hydroxylation and deoxygenation of lipids at both gene and protein levels in SCID mouse livers, but not in the h-heps of chimeric mouse livers, supporting the studies with h-PPARα-transgenic mice, a hitherto reliable model for studying the regulation of h-PPARα in the h-liver in most respects, except the induction of the peroxisome proliferation. This study indicates the importance of not only h-PPARα gene but also h-heps themselves to correctly predict effects of fibrates on h-livers, and, therefore, suggests that the chimeric mouse is a currently available, consistent, and reliable model to obtain pharmaceutical data concerning the effects of fibrates on h-livers.Entities:
Keywords: PPARα; fenofibrate; human hepatocytes; humanized mice
Mesh:
Substances:
Year: 2014 PMID: 25107573 DOI: 10.1177/0192623314544378
Source DB: PubMed Journal: Toxicol Pathol ISSN: 0192-6233 Impact factor: 1.902